Drug Guidance for Subsidy 02/09/2024 Endothelin receptor antagonists for treating pulmonary arterial hypertension The Ministry of Health’s Drug Advisory Committee has recommended: Ambrisentan 5 mg and 10 mg ... See all × 02/09/2024 Endothelin receptor antagonists for treating pulmonary arterial hypertension The Ministry of Health’s Drug Advisory Committee has recommended: Ambrisentan 5 mg and 10 mg tablets for treating adults with a confirmed diagnosis of WHO Functional Class II or III pulmonary arterial hypertension (PAH) who have one of the following PAH aetiologies: Idiopathic PAH; Heritable or familial PAH; PAH associated with connective tissue disease; Anorexigen-induced PAH; or PAH associated with HIV infection. Subsidy status RAmbrisentan 5 mg and 10 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication. NRMAF assistance does not apply to bosentan 62.5 mg and 125 mg tablets, and macitentan 10 mg tablet.
Post Marketing Information PMG 09/12/2016 Patient Medication Guide: PROART Film-coated Tablets 62.5 mg and 125 mg
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Tablet, Film Coated 62.5 mg KK Women's and Children's Hospital Tablet, Film Coated 125 mg National Heart Centre National University Hospital
ORAL Select a brand starting with the letter: P PROART FILM COATED TABLETS 125MG [SIN15132P] PROART FILM COATED TABLETS 62.5MG [SIN15133P]